复发/难治性多发性骨髓瘤靶向治疗药物——特立妥单抗

Recurrent/refractory multiple myeloma targeted therapy drug:teclistamab

特立妥单抗是一种治疗复发/难治性多发性骨髓瘤(RRMM)的靶向CD3和B细胞成熟抗原(BCMA)的双特异性抗体,分别于2022年8月和10月在欧盟和美国获批上市。临床研究显示,特立妥单抗对既往接受过≥3线治疗的RRMM患者可产生深度、持久的缓解,且耐受性良好。本品常见的不良反应包括血液系统不良反应、细胞因子释放综合征、感染、神经毒性、肝脏毒性、发热等。本文将对特立妥单抗的药理作用、药动学和临床疗效评价等进行介绍,以期为临床合理用药提供参考。

Teclistamab,a bispecific antibody targeting CD3 and B-cell maturation antigen(BCMA)for the treatment of relapsed/refractory multiple myeloma(RRMM),was approved for marketing in the European Union and the United States in August 2022 and October 2022,respectively.Clinical studies have shown that teclistamab produces profound,durable responses and is well tolerated in patients with RRMM who have received more than three prior lines of therapy.Common adverse reactions include hematological adverse reactions,cytokine release syndrome(CRS),infection,neurotoxicity,hepatotoxicity,and pyrexia.In this paper,the pharmacological effects,pharmacokinetics and clinical efficacy evaluation of teclistamab were reviewed,so as to provide references for clinical rational use of drug.